Abraham; Michal

Patent Applications and Registrations

Patent applications and USPTO patent grants for Abraham; Michal.The latest application filed is for "small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth".

Company Profile

3.14.14

Abraham; Michal - Mevasseret Zion IL
Abraham; Michal - Presov SK
Abraham; Michal - Mevaseret Zion N/A IL
Abraham; Michal - Mevassert Zion IL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Small molecules for inhibiting chemokine activity and/or cancer cells growth Grant 11,129,824 - Peled , et al. September 28, 2	2021-09-28
Small molecules against cancer Grant 10,646,465 - Peled , et al.	2020-05-12
Small Molecules For Inhibiting Chemokine Activity, A Kinase Activity And/or Cancer Cells Growth App 20190336492 - PELED; Amnon ; et al.	2019-11-07
Small Molecules Against Cancer App 20190240188 - PELED; Amnon ; et al.	2019-08-08
Methods Of Treating Acute Myeloid Leukemia With A Flt3 Mutation App 20190038703 - PELED; Amnon ; et al.	2019-02-07
Cxcr4 Binding Agents For Treatment Of Diseases App 20180221393 - PELED; Amnon ; et al.	2018-08-09
Chemokine Binding Polypeptides For Treating Autoimmunity, And Inflammation App 20170015708 - ABRAHAM; Michal ; et al.	2017-01-19
Chemokine binding polypeptides for treating autoimmunity and inflammation Grant 9,493,557 - Abraham , et al. November 15, 2	2016-11-15
Automatic file system migration to a network attached storage system Grant 9,430,483 - Cowan , et al. August 30, 2	2016-08-30
Peptide therapy for increasing platelet levels Grant 9,427,456 - Abraham , et al. August 30, 2	2016-08-30
Methods Of Treating Acute Myeloid Leukemia With A Flt3 Mutation App 20160243187 - PELED; Amnon ; et al.	2016-08-25
T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy Grant 8,765,683 - Peled , et al. July 1, 2	2014-07-01
Novel Chemokine Binding Polypeptides Capable Of Inhibiting The Course Of Autoimmunity, Inflammation And Cancer App 20140154249 - ABRAHAM; Michal ; et al.	2014-06-05
Chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer Grant 8,685,398 - Abraham , et al. April 1, 2	2014-04-01
T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation Grant 8,663,651 - Peled , et al. March 4, 2	2014-03-04
Methods For Obtaining A Therapeutically Effective Amount Of Hematopoietic Precursor Cells And Long Term Engraftment Thereof App 20140030211 - PELED; Amnon ; et al.	2014-01-30
Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof Grant 8,455,450 - Peled , et al. June 4, 2	2013-06-04
T-140 Peptide Analogs Having Cxcr4 Super-agonist Activity For Cancer Therapy App 20120207748 - Peled; Amnon ; et al.	2012-08-16
Peptide Therapy For Increasing Platelet Levels App 20120094907 - Abraham; Michal ; et al.	2012-04-19
Novel Chemokine Binding Polypeptides Capable Of Inhibiting The Course Of Autoimmunity, Inflammation And Cancer App 20120087921 - Abraham; Michal ; et al.	2012-04-12
T-140 Peptide Analogs Having Cxcr4 Super-agonist Activity For Cancer Therapy App 20100184694 - Peled; Amnon ; et al.	2010-07-22
T-140 Peptide Analogs Having Cxcr4 Super-agonist Activity For Bone Marrow Recovery App 20100166715 - Peled; Amnon ; et al.	2010-07-01
T-140 Peptide Analogs Having Cxcr4 Super-agonist Activity For Immunomodulation App 20100143334 - Peled; Amnon ; et al.	2010-06-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.